| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Liposarcoma, a malignant mesenchymal tumor showing lipogenic differentiation, should be diagnosed correctly and treated appropriately. In order to improve the accuracy of pathologic diagnosis of liposarcoma, several studies were carried out. The results are as follows: p16-immunostaining is useful for the differentiation between intramuscular lipoma and atypical lipomatous tumor (ALT); ALT and dedifferentiated liposarcoma (DDLPS) are characterized by the overexpression of MDM2 protein and the amplification of MDM2 gene; and ALT/DDLPS are more infiltrative than previously thought. Hopefully, the results will improve the diagnostic accuracy and the therapeutic strategies.
|
